Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway

PURPOSE: New direct-acting antiviral (DAA) drugs have revolutionized the treatment of hepatitis C in recent years. OBJECTIVE: Our objective was to analyse the cost effectiveness of combinations of different DAAs compared with ribavirin and peginterferon-α-2a, taking into account rebates from tender...

Descripción completa

Detalles Bibliográficos
Autores principales: Wisløff, Torbjørn, White, Richard, Dalgard, Olav, Amundsen, Ellen J., Meijerink, Hinta, Løvlie, Astrid Louise, Kløvstad, Hilde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906515/
https://www.ncbi.nlm.nih.gov/pubmed/29396744
http://dx.doi.org/10.1007/s40273-017-0604-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906515/
https://www.ncbi.nlm.nih.gov/pubmed/29396744
http://dx.doi.org/10.1007/s40273-017-0604-3

Ejemplares similares